Neurocrine Biosciences Inc (STU:NB3)
€ 107.2 1.9 (1.8%) Market Cap: 10.83 Bil Enterprise Value: 10.11 Bil PE Ratio: 35.07 PB Ratio: 4.67 GF Score: 88/100

Neurocrine Biosciences Inc at Cowen Healthcare Conference (Virtual) Transcript

Mar 02, 2021 / 06:30PM GMT
Release Date Price: €90 (+0.18%)
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good afternoon, and welcome once again to Cowen and Company's 41st Healthcare Conference. Hopefully, our only virtual edition. I'm Phil Nadeau, a biotech analyst here at Cowen, and it's my pleasure to moderate a fireside chat with Neurocrine Biosciences. We're really happy to have with us from sunny San Diego, Kevin Gorman, Neurocrine's CEO.

Questions & Answers

Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Kevin, to kick things off, could you give us a brief state of the company overview, biggest strengths, biggest challenges? And what needs to happen to drive outperformance over the next year?

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Yes. Thank you, Phil, and thank you, Cowen, for the opportunity to speak here today. I will be making forward-looking statements, so I direct people to our recent SEC filings. Neurocrine is a dyed-in-the-wool

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot